New study explores how Alzheimer's drug affects patients and families in daily life
NCT ID NCT06285448
First seen Feb 01, 2026 · Last updated May 24, 2026 · Updated 18 times
Summary
This study aims to see if it's possible to create a registry that tracks how lecanemab, a new Alzheimer's drug, affects patients and their care partners in real-world settings. Researchers will enroll 20 people with Alzheimer's who are eligible for lecanemab and their care partners. They will collect information on quality of life, stress, and burden through surveys and interviews over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HealthPartners Neuroscience Center
Saint Paul, Minnesota, 55130, United States
Conditions
Explore the condition pages connected to this study.